Wellness Lab BlogBook
    Back to Wellness Lab Blog
    Weight And MetabolismPatient Resources

    Retatrutide Access Update: A September 2026 Historical Notice And Current Regulatory Context

    Newsletter issue · 2026-09-25

    A historical record of a September 2026 pharmacy access notice for compounded retatrutide, with current FDA context: retatrutide is not FDA-approved and cannot be used in compounding under federal law.

    By Wellness Lab.

    An open desk calendar, brass hourglass, and notebook on a clean ivory surface representing time and planning

    This page preserves a time-sensitive access notice Wellness Lab shared with patients on September 24, 2026 as historical context, and adds the current regulatory context that applies now. It is not an offer to supply, order, or prescribe retatrutide, and no ordering or eligibility request is available through this page.

    What the September 24, 2026 notice said

    On September 24, 2026, Wellness Lab shared a time-sensitive notice that a pharmacy partner had told us it expected to stop filling compounded retatrutide prescriptions within approximately 15 to 30 days. The notice described the change as pharmacy-specific, subject to inventory and operational changes, and stated that future access was not yet known.

    That notice is retained here only as a historical record of what was communicated at the time. It does not represent current availability, and it should not be read as a statement that compounded retatrutide is an option today.

    Why retatrutide is not a routine option

    Retatrutide is an investigational medication and is not FDA-approved. Compounded preparations are not FDA-approved products and do not undergo FDA premarket review for safety, effectiveness, or quality.

    The FDA states that retatrutide cannot be used in compounding under federal law. This historical page does not offer compounded retatrutide, and this page does not invite patients to request it. Any prior pharmacy communication about availability reflected that partner's position at that time and cannot establish lawful or current availability.

    Where the verified regulatory source lives

    The current federal context summarized above is drawn from the FDA's public statements on unapproved GLP-1 drugs used for weight loss. The verified primary source is available on the FDA website and describes the agency's concerns about unapproved GLP-1 products and the legal limits on compounding these drugs.

    For any personal, non-urgent question about your own care, medications, or metabolic health, the appropriate next step is a clinical conversation with a licensed clinician rather than acting on a historical pharmacy notice.

    Clinical references

    • FDA: Concerns About Unapproved GLP-1 Drugs Used for Weight Loss — https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
    • FDA: Drug Alerts and Statements

    Key takeaways

    • Retatrutide is investigational, not FDA-approved, and cannot be used in compounding under federal law.
    • A September 2026 pharmacy communication about availability is preserved as history only; it cannot establish current or lawful availability.
    • No ordering, supply, discount, or eligibility request is offered through this page.

    Educational and historical notice only. Not medical advice, not an offer to supply or prescribe, and not a statement of current availability. Retatrutide is not FDA-approved and cannot be used in compounding under federal law. Patient-specific questions about medications or care require review by a licensed clinician.

    Have a non-urgent personal question? Book a Wellness Lab visit to discuss your care with Danielle Johnson, FNP-C.

    Book a Wellness Lab visit

    Related Wellness Lab articles